body { -ms-overflow-style: scrollbar; overflow-y: scroll; overscroll-behavior-y: none; } .errorContainer { background-color: #FFF; color: #0F1419; max-width: 600px; margin: 0 auto; padding: 10%; font-family: Helvetica, sans-serif; font-size: 16px; } .errorButton { margin: 3em 0; } .errorButton a { background: #1DA1F2; border-radius: 2.5em; color: white; padding: 1em 2em; text-decoration: none; } .errorButton a:hover, .errorButton a:focus { background: rgb(26, 145, 218); } .errorFooter { color: #657786; font-size: 80%; line-height: 1.5; padding: 1em 0; } .errorFooter a, .errorFooter a:visited { color: #657786; text-decoration: none; padding-right: 1em; } .errorFooter a:hover, .errorFooter a:active { text-decoration: underline; } #placeholder, #react-root { display: none !important; } body { background-color: #FFF !important; }

JavaScript is not available.

We’ve detected that JavaScript is disabled in this browser. Please enable JavaScript or switch to a supported browser to continue using twitter.com. You can see a list of supported browsers in our Help Center.

Terms of Service Privacy Policy Cookie Policy Imprint Ads info © 2023 Twitter, Inc.

Conversation

Statement by FDA Commissioner @SGottliebFDA, Director of FDA’s Center for Drug Evaluation and Research Janet Woodcock, M.D. and Director of FDA’s Center for Biologics Evaluation and Research Peter Marks, M.D. on Expanded Access –Looking Forward dlvr.it/R1pJqJ

5:07 PM · Mar 29, 2019

@brainmatters10

Replying to

Wow this is not going to provide much of anything for #ALS patients. Sad

@brainmatters10

Replying to

Very disappointing. This really provides little to nothing more for #ALS patients. Sad

2

1

@brainmatters10

Replying to

@brainmatters10

and

@SGottliebFDA wow no guidance documents or interim analysis for #ALS. Uggh

1